NDAC meeting on calendar
This article was originally published in The Tan Sheet
Executive Summary
FDA tentatively schedules a joint meeting of the Nonprescription Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee Sept. 14, the agency's Web site says. If the meeting is scheduled, the subject will not be known until FDA posts a Federal Register notice or updates meeting materials on its site. NDAC last met in June 2009, also with DSRM and the Life Support Drugs committee, to discuss acetaminophen (1"The Tan Sheet" Jan. 4, 2010, In Brief)
You may also be interested in...
FDA lays out 2010 advisory committee slate
The agency's tentative 1schedule for advisory committee meetings includes a Food meeting May 20-21 and Pediatric sessions in March, June, September and December. FDA's calendar, published Dec. 30 in the Federal Register, also pencils in meetings for both the Risk Communication panel and Science Board in February, May, August and November. The Nonprescription Drug Advisory Committee has not had tentative or firm meeting dates set. NDAC last met in June 2009 for a joint session regarding acetaminophen with the Drug Safety and Risk Management and Anesthetic and Life Support Drugs committees (2"The Tan Sheet" July 6, 2009)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.